RT Journal Article
T1 Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.
A1 Lodi, Sara
A1 Günthard, Huldrych F
A1 Gill, John
A1 Phillips, Andrew N
A1 Dunn, David
A1 Vu, Quang
A1 Siemieniuk, Reed
A1 Garcia, Federico
A1 Logan, Roger
A1 Jose, Sophie
A1 Bucher, Heiner C
A1 Scherrer, Alexandra U
A1 Reiss, Peter
A1 van Sighem, Ard
A1 Boender, T Sonia
A1 Porter, Kholoud
A1 Gilson, Richard
A1 Paraskevis, Dimitrios
A1 Simeon, Metallidis
A1 Vourli, Georgia
A1 Moreno, Santiago
A1 Jarrin, Inmaculada
A1 Sabin, Caroline
A1 Hernán, Miguel A
AB For people living with HIV, major guidelines in high-income countries recommend testing for transmitted drug resistance (TDR) to guide the choice of first-line antiretroviral therapy (ART). However, individuals who fail a first-line regimen can now be switched to one of several effective regimens. Therefore, the virological and clinical benefit of TDR testing needs to be evaluated. We included individuals from the HIV-CAUSAL Collaboration who enrolled  Of 25,672 eligible individuals (82% males, 52% diagnosed in 2010 or later), 17,189 (67%) were tested for TDR within 3 months of baseline. Of these, 6% had intermediate- or high-level TDR to any antiretroviral drug. The estimated 5-year proportion virologically suppressed was 77% under TDR testing and 74% under no TDR testing; HR 1.06 (95% confidence interval: 1.03 to 1.19). The estimated 5-year risk of AIDS or death was 6% under both strategies; HR 1.03 (95% confidence interval: 0.95 to 1.12). TDR prevalence was low. Although TDR testing improved virological response, we found no evidence that it reduced the incidence of AIDS or death in first 5 years after diagnosis.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14723
UL http://hdl.handle.net/10668/14723
LA en
DS RISalud
RD Apr 9, 2025